Listen Listen
Add to my selection
  • History
  • Technical informations
Share Print

TAGRISSO

Medicine - Posted on May 30 2022
Active substance (DCI)
  • osimertinib
history (4)
  • Economic analysis
    1/19/22

    TAGRISSO (osimertinib) - Cancer bronchique non à petites cellules (CBNPC)
    Key points Favourable opinion for reimbursement only in the adjuvant treatment after complete tumour resection and after adj...
    CAV :
    54321
    icône flèche
  • 3/20/20

    TAGRISSO (osimertinib)
    Key points Favourable opinion for reimbursement as monotherapy in the first-line treatment of adult patients with locally ad...
    CAV :
    54321
    icône flèche
  • Economic analysis
    9/13/17

    TAGRISSO (osimertinib), tyrosine kinase inhibitor
    Substantial actual benefit and minor improvement compared with chemotherapy combining a platinum salt with pemetrexed in pat...
    CAV :
    54321
    icône flèche
  • Economic analysis
    9/21/16

    TAGRISSO (osimertinib), tyrosine kinase inhibitor
    No clinical benefit demonstrated in the treatment of locally-advanced or metastatic non-small cell lung cancer with EGFR T79...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01EB04
Manufacturer
ASTRAZENECA
Presentation

TAGRISSO 40 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 4 4)

TAGRISSO 80 mg, comprimés pelliculés
30 plaquettes aluminium de 1 comprimé - (Code CIP : 34009 300 476 5 1)

All our publications
    Drug therapy Health economics Respiratory tract cancers
  • fr Français
  • en English
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
vXLr3Su20bP48XUA